History and principles of antiviral and anticancer vaccination in cervical cancer

Terri L. Cornelison, Edward L. Trimble

Research output: Contribution to journalReview article

Abstract

More than 11% of the global cancer incidence in females is due to human papillomavirus (HPV) infections, with HPV genotype 16 the most prevalent viral type to infect the cervix. HPV vaccines currently target HPV 16 genes E6 and E7, constitutively expressed in cervical cancer cells; and L1 and L2, HPV surface antigens. Successful vaccination to combat cervical cancer requires two vaccine strategies: an antiviral vaccine to prevent viral infection (prophylactic vaccination), and an anticancer vaccine to eliminate both virally-infected cells and virally-induced tumor cells (therapeutic vaccination).

Original languageEnglish (US)
Pages (from-to)204-209
Number of pages6
JournalCME Journal of Gynecologic Oncology
Volume9
Issue number3 PART 3
StatePublished - Dec 1 2004

    Fingerprint

Keywords

  • Anticancer vaccines
  • Antiviral vaccines
  • Cervical cancer
  • HPV vaccines

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this